NDA 021875 · Nuvo Pharms
Nuvigil
Armodafinil · Oral
Last checked: Nov 20, 2026Latest source record: Feb 7, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2007
Jun 15, 2007
Approved uses
1
Original approval plus efficacy supplements
Registered trials
56
22 Phase 3, 1 recruiting
FAERS reports
21,062
9,699 serious, 326 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 24, 2026.
NUVIGIL is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Limitations of Use In OSA, NUVIGIL is indicated to treat excessive sleepiness and not as treatment for the underlying obstruction. If continuous positive airway pressure (CPAP) is the treatment of choice for a patient, a maximal effort to treat with CPAP for an adequate period of time should be made prior to initiating NUVIGIL for excessive sleepiness. NUVIGIL is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). ( 1 ) Limitations of Use In OSA, NUVIGIL is indicated to treat excessive sleepiness and not as treatment for the underlying obstruction.
Mechanism: The mechanism(s) through which armodafinil promotes wakefulness is unknown. Armodafinil (R-modafinil) has pharmacological properties similar to those of modafinil (a mixture of R- and S-modafinil), to the extent tested in animal and in vitro studies. The R- and S-enantiomers have similar pharmacological actions in animals. Armodafinil and modafinil have wake-promoting actions similar to sympathomimetic agents including amphetamine and methylphenidate, although their pharmacologic profile is not identical to that of the sympathomimetic amines. Modafinil-induced wakefulness can be attenuated by...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 15, 2007 Original approval · Type 5 - New Formulation or New Manufacturer ReviewMedication GuideLetter
5 products under this application
- NUVIGIL · ARMODAFINIL 150MG · TABLET, ORAL · Prescription · TE AB
- NUVIGIL · ARMODAFINIL 50MG · TABLET, ORAL · Prescription · TE AB
- NUVIGIL · ARMODAFINIL 250MG · TABLET, ORAL · Prescription · TE AB
- NUVIGIL · ARMODAFINIL 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
- NUVIGIL · ARMODAFINIL 200MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Armodafinil" as an intervention, any sponsor and status, largest first.
- Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I DisorderPivotal-lookingTerminated
CephalonIndustry
NCT01121536 · 867 participants · Start Apr 30, 2010 · Primary completion Oct 31, 2013
Drug: Armodafinil · For: Depression
Sites: Birmingham, Alabama; Anaheim, California; Cerritos, California · 158 sites in all
- Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive SleepinessPivotal-lookingCompleted
CephalonIndustry
NCT00228553 · 743 participants · Start May 2004
Drug: Armodafinil 100 to 250 mg/day · For: Excessive Daytime Sleepiness; Narcolepsy; Obstructive Sleep Apnea/Hypopnea Syndrome and 1 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Hot Springs, Arkansas · 100 sites in all
- Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I DisorderPivotal-lookingCompleted
CephalonIndustry
NCT01072630 · 492 participants · Start Mar 2010 · Primary completion Nov 2012
Drug: Armodafinil; Placebo · For: Depression
Sites: Birmingham, Alabama; Anaheim, California; Cerritos, California · 92 sites in all
- A Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I DisorderPivotal-lookingCompleted
CephalonIndustry
NCT01072929 · 433 participants · Start Jan 2010 · Primary completion Mar 2012
Drug: Armodafinil; Placebo · For: Depression
Sites: Birmingham, Alabama; Beverly Hills, California; Garden Grove, California · 40 sites in all
- Study of the Effect of Armodafinil Treatment in Healthy Subjects With Excessive Sleepiness Associated With Jet Lag DisorderPivotal-lookingCompleted
CephalonIndustry
NCT00758498 · 427 participants · Start Sep 2008 · Primary completion Feb 2009
Drug: armodafinil; armodafinil and 1 more · For: Excessive Sleepiness
Sites: Atlanta, Georgia; Crestview, Kentucky; New York, New York · 4 sites in all
- Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I DisorderPivotal-lookingCompleted
CephalonIndustry
NCT01305408 · 399 participants · Start Mar 2011 · Primary completion Jul 2013
Drug: Armodafinil; Placebo · For: Depression
Sites: Birmingham, Alabama; Sherman Oaks, California; Temecula, California · 130 sites in all
- Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome(OSAHS)Pivotal-lookingCompleted
CephalonIndustry
NCT00078325 · 395 participants · Start Feb 2004 · Primary completion Nov 2004
Drug: Armodafinil 250 mg/day; Armodafinil 150 mg/day and 1 more · For: Obstructive Sleep Apnea; Hypopnea
- Efficacy and Tolerability of Armodafinil in Adults With Excessive Sleepiness Associated With Shift Work DisorderPivotal-lookingCompleted
CephalonIndustry
NCT01080807 · 385 participants · Start Mar 2010 · Primary completion Oct 2010
Drug: Armodafinil; Matching Placebo · For: Excessive Sleepiness
Sites: Phoenix, Arizona; Tucson, Arizona; Hot Springs, Arkansas · 63 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective1,579
- fatigue1,525
- nausea1,487
- headache1,411
- anxiety1,187
- somnolence1,110
- depression1,021
- insomnia986
- feeling abnormal961
- fall897
- dizziness880
- weight decreased748
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2008 | 4 |
| 2009 | 59 |
| 2010 | 202 |
| 2011 | 445 |
| 2012 | 2,692 |
| 2013 | 763 |
| 2014 | 820 |
| 2015 | 2,028 |
| 2016 | 5,261 |
| 2017 | 1,670 |
| 2018 | 1,525 |
| 2019 | 1,432 |
| 2020 | 1,044 |
| 2021 | 540 |
| 2022 | 622 |
| 2023 | 681 |
| 2024 | 612 |
| 2025 | 399 |
| 2026 | 263 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Nuvigil (Armodafinil)
2024 spending
$3.5M
Beneficiaries
386
2,320 claims
Per beneficiary
$9,047
$34.26 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $5,887,531 |
| 2021 | $4,764,572 |
| 2022 | $4,663,639 |
| 2023 | $3,760,951 |
| 2024 | $3,492,163 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline.
Maski K, Trotti LM, Kotagal S, et al. · J Clin Sleep Med 2021 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment.
Maski K, Trotti LM, Kotagal S, et al. · J Clin Sleep Med 2021 · Meta-Analysis, Research Support, N.I.H., Extramural
- Modafinil/armodafinil in obstructive sleep apnoea: a systematic review and meta-analysis.
Chapman JL, Vakulin A, Hedner J, et al. · Eur Respir J 2016 · Meta-Analysis, Systematic Review
- Armodafinil for fibromyalgia fatigue.
Schwartz TL, Siddiqui UA, Raza S, et al. · Ann Pharmacother 2010 · Letter, Randomized Controlled Trial
- Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder.
Ketter TA, Yang R, Frye MA · J Affect Disord 2015 · Multicenter Study, Randomized Controlled Trial
- Interventions for the management of fatigue in adults with a primary brain tumour.
Day J, Yust-Katz S, Cachia D, et al. · Cochrane Database Syst Rev 2022 · Research Support, Non-U.S. Gov't, Systematic Review
Sponsor: Nuvo Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.